Clinical Research Directory
Browse clinical research sites, groups, and studies.
Test of CD47-SIRPα Inhibitors on the Immune Microenvironment Colon Cancer
Sponsor: Institut Paoli-Calmettes
Summary
Our goal is to create novel CD47-SIRPα inhibitors using small molecules to reverse TAM-mediated immune suppression and restore anti-tumor immunity in CRCs. Our program uses structure-based drug design to create selective and potent small molecule inhibitors of SIRPα-CD47 to target the tumor microenvironment with greater efficacy and lower toxicity than CD47-targeting antibodies. . In order to study the activity of CD47-SIRPα inhibitors on the immune microenvironment of tumors, we propose to use organoids derived from biopsies of patients with colon cancer. Tumoroids preserve the patient's tumor stroma (including myeloid cells) and provide an accurate in vitro model of complex tumor immune interaction for the evaluation of immunotherapies.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
115
Start Date
2023-01-09
Completion Date
2027-01-09
Last Updated
2024-10-09
Healthy Volunteers
No
Conditions
Interventions
BLOOD AND TUMOR
sampling of 24 ml of peripheral blood and samples of colon cancers with healthy tissue in parallel on the surgery piece
Locations (1)
Institut Paoli Calmettes
Marseille, France